JABSOM covers our new collaboration with Neuraltus Pharamceuticals: a Phase 1b study of NP001 in patients with mild-to-moderate Alzheimer’s Disease. Check it out below:

“Given the key role inflammatory monocytes and macrophages may play in the progression of Alzheimer’s disease, researching immune regulators – like NP001 – is critical to understanding more about this serious and complex disease.” – Dr. Beau Nakamoto

“This is the first clinical study of NP001 in Alzheimer’s disease and we look forward to examining the results to see whether the compound impacts inflammation levels in this patient population.” – Rich Casey, Neuraltus Pharmaceutals CEO

“This trial wouldn’t be happening in Hawaiʻi without the RMATRIX (Multidisciplinary And Translational Research Infrastructure Expansion) Program at JABSOM, which supports the mentoring of junior scientists and the professional relationships forged through scientific collaboration.” – Dr. Cecilia Shikuma

UH Medical School: Phase 1b study announced of NP001 in patients with mild-to-moderate Alzheimer’s Disease